icon-menu
icon-menu

Products

Bisoprolol, 5 mg tablets

Drug formTablets

ATC categoryCardiology, angiology

ATC subcategoryAdrenoblockers

Brand nameBisoprolol

Generic nameBisoprolol

Qualitative and quantitative composition

Each coated-tablet contains bisoprolol fumarate 5 mg

For the full list of excipients, see section List of excipients.

Posology and method of administration

Standard treatment of CHF consists of an ACE inhibitor (or an angiotensin receptor blocker in case of intolerance to ACE inhibitors), a beta-blocker, diuretics, and when appropriate cardiac glycosides. Patients should be stable (without acute failure) when bisoprolol treatment is initiated.

It is recommended that the treating physician should be experienced in the management of chronic heart failure.

Transient worsening of heart failure, hypotension, or bradycardia may occur during the titration period and thereafter.

 

Posology

Titration phase

The treatment of stable chronic heart failure with bisoprolol requires a titration phase

The treatment with bisoprolol is to be started with a gradual uptitration according to the following steps:

  • 1.25 mg once daily for 1 week, if well tolerated increase to
  • 2.5 mg once daily for a further week, if well tolerated increase to
  • 3.75 mg once daily for a further week, if well tolerated increase to
  • 5 mg once daily for the 4 following weeks, if well tolerated increase to
  • 7.5 mg once daily for the 4 following weeks, if well tolerated increase to
  • 10 mg once daily for the maintenance therapy.

The maximum recommended dose is 10 mg once daily.

Close monitoring of vital signs (heart rate, blood pressure) and symptoms of worsening heart failure is recommended during the titration phase. Symptoms may already occur within the first day after initiating the therapy.

Treatment modification

If the maximum recommended dose is not well tolerated, gradual dose reduction may be considered.

In case of transient worsening of heart failure, hypotension, or bradycardia reconsideration of the dosage of the concomitant medication is recommended. It may also be necessary to temporarily lower the dose of bisoprolol or to consider discontinuation.

The reintroduction and/or uptitration of bisoprolol should always be considered when the patient becomes stable again.

If discontinuation is considered, gradual dose decrease is recommended, since abrupt withdrawal may lead to acute deterioration of the patients condition.

Treatment of stable chronic heart failure with bisoprolol is generally a long-term treatment.

Patients with hepatic or renal impairment

There is no information regarding pharmacokinetics of bisoprolol in patients with chronic heart failure and with impaired hepatic or renal function. Uptitration of the dose in these populations should therefore be made with additional caution.

Older people

No dosage adjustment is required.

Paediatric population

There is no paediatric experience with bisoprolol, therefore its use cannot be recommended in paediatric patients.

 

Method of administration

Bisoprolol tablets should be taken in the morning and can be taken with food. They should be swallowed with liquid and should not be chewed.

Pharmacological properties

Pharmacotherapeutic group: Beta blocking agents, selective

ATC Code: C07AB07

Pharmaceutical particulars

List of excipients

Tablet core:

microcrystalline cellulose,

povidone,

sodium starch glycolate,

magnesium stearate,

maize starch,

aerosol 200;

Tablet coating:

talc purified,

propylene glycol,

titanium dioxide,

hypromellose,

sunset yellow FCF (E110),

color red (E129).

For more detailed information about the drug, click: http://pharm.cals.am/pharm/data/drug_134482/1734095746965.pdf